LYPH.F logo

Luye Pharma Group OTCPK:LYPH.F Stock Report

Last Price

US$0.37

Market Cap

US$1.4b

7D

0%

1Y

n/a

Updated

21 Jul, 2024

Data

Company Financials +

Luye Pharma Group Ltd.

OTCPK:LYPH.F Stock Report

Market Cap: US$1.4b

LYPH.F Stock Overview

An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.

LYPH.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Luye Pharma Group Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Luye Pharma Group
Historical stock prices
Current Share PriceHK$0.37
52 Week HighHK$0.43
52 Week LowHK$0.37
Beta0.78
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-50.67%

Recent News & Updates

Recent updates

Shareholder Returns

LYPH.FUS PharmaceuticalsUS Market
7D0%-3.3%-2.1%
1Yn/a17.0%19.0%

Return vs Industry: Insufficient data to determine how LYPH.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LYPH.F performed against the US Market.

Price Volatility

Is LYPH.F's price volatile compared to industry and market?
LYPH.F volatility
LYPH.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: LYPH.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LYPH.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19945,270Dian Bo Liuwww.luye.cn

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.

Luye Pharma Group Ltd. Fundamentals Summary

How do Luye Pharma Group's earnings and revenue compare to its market cap?
LYPH.F fundamental statistics
Market capUS$1.36b
Earnings (TTM)US$73.26m
Revenue (TTM)US$844.99m

18.5x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYPH.F income statement (TTM)
RevenueCN¥6.14b
Cost of RevenueCN¥1.94b
Gross ProfitCN¥4.20b
Other ExpensesCN¥3.67b
EarningsCN¥532.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.14
Gross Margin68.44%
Net Profit Margin8.67%
Debt/Equity Ratio61.7%

How did LYPH.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.